Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity

Journal of Clinical Investigation

Volumn 101, Issue 5, 1998, Pages 1156-1162

  Laine, Hanna ^a   Yki Järvinen, Hannele ^b   Kirvelä, Olli ^a   Tolvanen, Tuula ^a   Raitakari, Maria ^a   Solin, Olof ^a   Haaparanta, Merja ^a   Knuuti, Juhani ^a   Nuutila, Pirjo ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Blood flow; Bradykinin; Insulin resistance; Obesity; Positron emission tomography

Indexed keywords

BRADYKININ; GLUCOSE; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GLUCOSE TRANSPORT SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; MALE; MUSCLE BLOOD FLOW; OBESITY; PRIORITY JOURNAL; SKELETAL MUSCLE; VASODILATATION;

EID: 2642611091     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1065     Document Type: Article

References (55)

1. DeFronzo, R.A., V. Soman, R. Sherwin, R. Hendler, and P. Felig. 1978. Insulin binding to monocytes and insulin action in human obesity, starvation and refeeding. J. Clin. Invest. 62:204-213.
2. Laakso, M., S.V. Edelman, J.M. Olefsky, G. Brechtel, P. Wallace, and A.D. Baron. 1990. Kinetics of in vivo muscle insulin-mediated glucose uptake in human obesity. Diabetes. 39:965-974.
3. Castillo, C., C. Bogardus, R. Bergman, P. Thuillez, and S. Lillioja. 1994. Interstitial insulin concentrations determine glucose uptake rates but not insulin resistance in lean and obese men. J. Clin. Invest. 93:10-16.
4. Steinberg, H.O., H. Chaker, R. Learning, A. Johnson, G. Brechtel, and A.D. Baron. 1996. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Om. Invest. 97: 2601-2610.
5. Mandarino, L.J., A. Consoli, A. Jain, and D.E. Kelley. 1996. Interaction of carbohydrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM. Am. J. Physiol. 270:E463-E470.
6. Scherrer, U., D. Randin, P. Vollenweider, L. Vollenweider, and P. Nicod. 1994. Nitric oxide release accounts for insulin's vascular effects in humans. J. Clin. Invest. 94:2511-2515.
7. Steinberg, H.O., G. Brechtel, A. Johnson, N. Fireberg, and A.D. Baron. 1994. Insulin-mediated skeletal muscle vasodilatation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J. Clin. Invest. 94: 1172-1179.
8. Baron, A.D., H. Steinberg, G. Brechtel, and A. Johnson. 1994. Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. Am. J. Physiol. 266:E248-E253.
9. Baron, A.D., H.O. Steinberg, H. Chaker, R. Leaming, A. Johnson, and G. Brechtel. 1995. Insulin-mediated skeletal muscle vasodilatation contributes to both insulin sensitivity and responsiveness in lean humans. J. Clin. Invest. 96: 786-792.
10. Nakane, M., H.H. Schmidt, J.S. Pollock, U. Fostermann, and F. Murad. 1993. Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS (Fed. Eur. Biochem. Soc.) Lett. 316:175-180.
11. Balon, T.W., and J.L. Nadler. 1994. Nitric oxide release is present from incubated skeletal muscle preparations. J. Appl. Physiol. 77:2519-2521.
12. Balon, T.W., and J.L. Nadler. 1997. Evidence that nitric oxide increases glucose transport in skeletal muscle. J. Appl. Physiol. 82:359-363.
13. Natali, A., R. Bonadonna, D. Santoro, A.Q. Galvan, S. Baldi, S. Frascerra, C. Palombo, S. Ghione, and E. Ferrannini. 1994. Insulin resistance and vasodilatation in essential hypertension. Studies with adenosine. J. Clin. Invest. 94:1570-1576.
14. 18F]fluoro-deoxy-glucose and positron emission tomography. J. Clin. Invest. 97:1741-1747.
15. D'Orleans-Juste, P., S. Dion, J. Mizrahi, and D. Regoli. 1985. Effects of peptides and non-peptides on isolated arterial smooth muscles: role of endothelium. Eur. J. Pharmacol. 114:9-21.
16. G-monomethy-L-arginine on kinin-induced vasodilatation in the human forearm. Br. J. Clin. Pharmacol. 38:307-310.
17. Shimojo, N., T.G. Pickens, H.S. Margolius, and R.K. Mayfield. 1987. Tissue kallikrein and bradykinin do not have direct insulin-like actions on skeletal muscle glucose utilization. Biol. Chem. Hoppe-Seyler. 368:1355-1361.
18. Rosen, P., J. Eckel, and H. Reinauer. 1983. Influence of bradykinin on glucose uptake and metabolism studied in isolated cardiac myocytes and isolated perfused rat hearts. Hoppe-Seyler's Z Physiol. Chem. 364:1431-1438.
19. Regoli, D., and J. Barabe. 1980. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32:1-46.
20. Yki-Järvinen, H., V.A. Koivisto, and S. Karonen. 1985. Influence of body composition on insulin clearance. Clin. Physiol. 5:45-52.
21. Stöcklin, G., V. Pike, C. Crouzel, J. Clark, C. Brihaye, B. Långtröm, C. Lemaire, G. Meyer, B. Nebeling, and S. Stone-Elander, editors. 1993. Radiochemistry automation for PET. In Radiopharmaceuticals for Positron Emission Tomography. Kluwer Academic Publishers. Netherlands. 45-90.
22. 18F]-fluoro-2-deoxy-D-glucose using ami-nopolyether supported nucleophilic substitution. J. Nucl. Med. 27:235-238.
23. 215O autoradiography and positron emission tomography, with respect to the dispersion of the input function. J. Cereb. Blood Flow Metab. 6:536-545.
24. Nuutila, P., V.A. Koivisto, J. Knuuti, U. Ruotsalainen, M. Teräs, M. Haaparanta, J. Bergman, O. Solin, L. Voipio-Pulkki, U. Wegelius, and H. Yki-Järvinen. 1992. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J. Clin. Invest. 89:1767-1774.
25. Kety, S.S. 1960. Theory of blood-tissue exchange and its application to measurement of diffusible substance. Methods Med. Res. 8:223-227.
26. Howard, B.E., M.D. Ginserg, W.R. Hassel, A.H. Lockwood, and P. Freed. 1983. On the uniqueness of cerebral blood flow measured by in vivo autoradiography. J. Cereb. Blood Flow Metab. 3:432-441.
27. 15-oxygen-water and PET. J. Nucl. Med. 38:314-319.
28. 14C]deoxy-glucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rats. J. Neurochem. 28:897-916.
29. Patlak, C.S., and R.G. Blasberg. 1985. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J. Cereb. Blood Flow Metab. 5:584-590.
30. 18F-deoxyglucose. J. Nucl. Med. 30:359-366.
31. DeFronzo, R.A., J.D. Tobin, and R. Andres. 1979. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237:E214-E223.
32. Kadish, A.H., R.L. Little, and J.C. Sternberg. 1968. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin. Chem. 14:116-131.
33. Kuzuya, H., P.M. Blix, D.L. Horwitz, D.F. Steiner, and A.H. Rubenstein. 1977. Determination of tree and total insulin and C-peptide in insulin-treated diabetics. Diabetes. 26:22-29.
34. Lillioja, S., C. Bogardus, D.M. Mott, A.L. Kennedy, W.C. Knowler. and B.V. Howard. 1985. Relationship between insulin-mediated glucose disposal and lipid metabolism in man. J. Clin. Invest. 75:1106-1115.
35. Laakso, M., S.V. Edelman, G. Brechtel, and A.D. Baron. 1990. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. J. Clin. Invest. 85:1844-1882.
36. Utriainen, T., R. Malmström, S. Mäkimattila, and H. Yki-Järvinen. 1995. Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia. 38:555-564.
37. Rabinowitz, D., and K.L. Zierler. 1962. Forearm metabolism in obesity and its response to intra-arterial insulin. Characterization of insulin resistance and evidence for adaptive hyperinsulinism. J. Clin. Invest. 41:2173-2181.
38. Jackson, R.A., N. Peters, U. Advani, G. Perry, J. Rogers, W.H. Brough, and T.R.E. Pilkington. 1973. Forearm glucose uptake during the oral glucose tolerance test in normal subjects. Diabetes. 22:442-458.
39. DeFronzo, R.A., E. Jacot, E. Jequier, E. Maeder, J. Wahren, and J.P. Felber. 1981. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes. 30:1000-1007.
40. DeFronzo, R.A., E. Ferrannini, R. Hendler, P. Felig, and J. Wahren. 1983. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes. 32:34-45.
41. Kelley, D., A. Mitrakou, H. Marsh, F. Schwenck, J. Benn. G. Sonnenberg, M. Arcangeli, T. Aoki, J. Sörensen, M. Berger, P. Sönksen, and J.E. Gerich. 1988. Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. J. Clin. Invest. 81:1563-1571.
42. Bonadonna, R.C., M.P. Saccomani, L. Seely, K.S. Zych, E. Ferrannini, C. Cobelli, and R.A. DeFronzo. 1993. Glucose transport in human skeletal muscle. The in vivo response to insulin. Diabetes. 42:181-198.
43. Vallance, P., J. Collier, and S. Moncada. 1989. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 2:997-1000.
44. Buchanan, T.A., H. Thawani, W. Kades, J.G. Modrali, F.A. Weaver, C. Laurei, R. Poppiti, A. Xiang, and W. Hsueh. 1993. Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. J. Clin. Invest. 92:720-726.
45. Jamerson, J.K., S.D. Nesbitt, J.V. Amerena, E. Grant, and S. Julius. 1996. Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects. Hypertension. 27:854-858.
46. Madar, Z., J. Zierath, L. Nolte, A. Thorne, H. Voet, and H. Wallberg-Henriksson. 1997. Human skeletal muscle nitric oxide synthase: characterization of its activity in obese subjects. Diabetes. 46:24A.
47. Yki-Järvinen, H., A.A. Young, C. Lamkin, and J.E. Foley. 1987. Kinetics of glucose disposal in whole body and across the forearm in man. J. Clin. Invest. 79:1713-1719.
48. Dohm, G.L., E.B. Tapscott, W.J. Pories, D.J. Dabbs, E.G. Flickinger, D. Meelheim, T. Fushiki, S.M. Atkinson, C.W. Elton, and J.F. Caro. 1988. An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J. Clin. Invest. 82:486-494.
49. Goodyear, L.J., F. Giorgino, L.A. Sherman, J. Carey, R.J. Smith, and G.L. Dohm. 1995. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J. Clin. Invest. 95:2195-2204.
50. Dinerman, J.L., C.J. Lowenstein, and S.H. Synder. 1993. Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease. Circ. Res. 73:217-222.
51. Welborn, T.A., and K. Wearne. 1979. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 2:154-160.
52. Pyörälä, K. 1979. Relationship of glucose tolerance and plasma insulin in the incidence of coronary heart disease. Results from two population studies in Finland. Diabetes Care. 2:131-141.
53. Zhang, B., J. Berger, J. Zhou, A. Elbrecht, S. Biswas, S. White-Carrington, D. Szalkowski, and D.E. Moller. 1996. Insulin-and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 271:31771-31774.
54. Nagasaka, Y., K. Kaku, K. Nakamura, and T. Kaneko. 1995. The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein. Biochem. Pharmacol. 50:1109-1111.
55. Noguchi, N., H. Sakai, Y. Kato, J. Tsuchiya, Y. Yamamoto, E. Niki, H. Horikoshi, and T. Kodama. 1996. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis. 123:227-234.